Nephros's gross profit for the
three
months ended in Mar. 2024 was $2.19 Mil. Nephros's gross profit for the trailing twelve months (TTM) ended in Mar. 2024 was $8.48 Mil.
Gross Margin % is calculated as gross profit divided by its revenue. Nephros's gross profit for the
three
months ended in Mar. 2024 was $2.19 Mil. Nephros's Revenue for the
three
months ended in Mar. 2024 was $3.52 Mil. Therefore, Nephros's Gross Margin % for the quarter that ended in Mar. 2024 was 62.10%.
Nephros had a gross margin of 62.10% for the quarter that ended in Mar. 2024 => Durable competitive advantage
During the past 13 years, the highestGross Margin % of Nephros was 68.59%. The lowest was 47.43%. And the median was 56.86%.
Warning Sign:
Nephros Inc gross margin has been in long-term decline. The average rate of decline per year is -1.3%.
Nephros Gross Profit Historical Data
The historical data trend for Nephros's Gross Profit can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Nephros's Gross Profit, along with its competitors' market caps and Gross Profit data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nephros's Gross Profit Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nephros's Gross Profit distribution charts can be found below:
* The bar in red indicates where Nephros's Gross Profit falls into.
Nephros Gross Profit Calculation
Gross Profit is the different between the sale prices and the cost of buying or producing the goods.
Nephros's Gross Profit for the fiscal year that ended in Dec. 2023 is calculated as
Gross Profit for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $8.48 Mil.
Gross Profit is the numerator in the calculation of Gross Margin.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
Nephros (NAS:NEPH) Gross Profit Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
Nephros had a gross margin of 62.10% for the quarter that ended in Mar. 2024 => Durable competitive advantage
Nephros Gross Profit Related Terms
Thank you for viewing the detailed overview of Nephros's Gross Profit provided by GuruFocus.com. Please click on the following links to see related term pages.
Nephros Inc is a commercial-stage company that develops and sells high performance water solutions to the medical and commercial markets. In medical markets, it sell water filtration products and waterborne pathogen detection products. In commercial markets, the company manufacture and sell water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The operating segments of the group are Water Filtration, Pathogen Detection and Renal Products of which key revenue is derived from Water Filtration segment.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NEPH has been successfully added to your 